Table 3.
Failed Scale-up | Universal ART | Test&Treat | |||||||
---|---|---|---|---|---|---|---|---|---|
New Infections 2020 | Total New Infections 2017–2020 | Total New Infections 2017–2050 | New infections2020 | Total New Infections 2017–2020 | Total New Infections 2017–2050 | New Infections 2020 | Total New Infections 2017–2020 | Total New Infections 2017–2050 | |
i) CD4 monitoring, no tracing | 13363 | 60182 (ref) | 326790 (ref) | infections | 53419 (ref) | 260908 (ref) | 9751 | 49422 (ref) | 241548 (ref) |
ii) CD4 monitoring, tracing | 13314 | 60023 (0.3%) | 324965 (0.6%) | 2020 | 53262 (0.3%) | 259498 (0.5%) | 9705 | 49268 (0.3%) | 240265 (0.5%) |
iii) CD4 monitoring, no interruptions | 12438 | 57218 (4.9%) | 293353 (10.2%) | 9955 | 50503 (5.5%) | 235083 (9.9%) | 8904 | 46553 (5.8%) | 218062 (9.7%) |
iv) 24-m VL monitoring, no tracing | 13284 | 59927 (0.4%) | 323868 (0.9%) | 10762 | 53168 (0.5%) | 258650 (0.9%) | 9678 | 49175 (0.5%) | 239495 (0.9%) |
v) 24-m VL monitoring, tracing | 13289 | 59942 (0.4%) | 324039 (0.8%) | 10766 | 53182 (0.4%) | 258782 (0.8%) | 9682 | 49190 (0.5%) | 239615 (0.8%) |
vi) 24-m VL monitoring, no interruptions | 12384 | 57044 (5.2%) | 291420 (10.8%) | 9903 | 50331 (5.8%) | 233591 (10.5%) | 8854 | 46384 (6.1%) | 216705 (10.3%) |
vii) 12-m VL monitoring, no tracing | 13232 | 59760 (0.7%) | 321959 (1.5%) | 10712 | 53003 (0.8%) | 257175 (1.4%) | 9630 | 49013 (0.8%) | 238153 (1.4%) |
viii) 12-m VL monitoring, tracing | 13154 | 59511 (1.1%) | 319122 (2.3%) | 10638 | 52758 (1.2%) | 254983 (2.3%) | 9559 | 48772 (1.3%) | 236160 (2.2%) |
ix) 12-m VL monitoring, no interruptions | 12312 | 56815 (5.6%) | 288888 (11.6%) | 9835 | 50106 (6.2%) | 231637 (11.2%) | 8789 | 46163 (6.6%) | 214927 (11.0%) |
Percentages in parentheses refer to the reduction compared with scenario (i) (first row) of the corresponding access scenario (Failed scale-up, Universal ART, or Test&Treat).
Abbreviations: ART, antiretroviral therapy; VL, viral load.